There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]
In anticipation of our Monday night teleconference on Provenge (see below for registration procedures) I am very happy to report that Dendreon is now detailing plans to move Provenge to earlier stages in the disease’s progress. At the American Society of Clinical Oncology (ASCO) meeting in Chicago which is winding down today, Dendreon unveiled plans [...]
Malecare Cancer Support's Advanced Prostate Cancer Program invites you to our teleconference on Provenge. The Teleconference will begin 6PM EDT, Monday, June 13, 2011. Please register at http://bit.ly/kKuByH Call in number and code will be emailed to you, along with info on how to ask your specific question of our guest. The teleconference will be [...]
Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
The battle to make sure that Provenge is available nationally (in the United States) to all men who meet the FDA approval requirements is continuing. We have made great steps through the “noise” that the community has made to date. We have successfully reached, what I believe is, the final step in insuring that Provenge [...]